Ontology highlight
ABSTRACT:
SUBMITTER: Hamid O
PROVIDER: S-EPMC4126516 | biostudies-literature | 2013 Jul
REPOSITORIES: biostudies-literature
Hamid Omid O Robert Caroline C Daud Adil A Hodi F Stephen FS Hwu Wen-Jen WJ Kefford Richard R Wolchok Jedd D JD Hersey Peter P Joseph Richard W RW Weber Jeffrey S JS Dronca Roxana R Gangadhar Tara C TC Patnaik Amita A Zarour Hassane H Joshua Anthony M AM Gergich Kevin K Elassaiss-Schaap Jeroen J Algazi Alain A Mateus Christine C Boasberg Peter P Tumeh Paul C PC Chmielowski Bartosz B Ebbinghaus Scot W SW Li Xiaoyun Nicole XN Kang S Peter SP Ribas Antoni A
The New England journal of medicine 20130602 2
<h4>Background</h4>The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.<h4>Methods</h4>We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior ...[more]